Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Kevin Ronald Sayer

Market Cap

53.47 Billion USD

Sector

Healthcare

Website

https://www.dexcom.com

Last Update

2/22/2024, 12:00:00 PM

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

Read More

Overview

Value

3

Growth

59

Health

56

Management

80

Analyst Opinion

94

Total

58

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Low risk of bankruptcy
  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Price-to-earnings ratio of 81.8 is higher than the market average (19.6x)
  • Dividend could be at risk

Market Peers

DXCM

Key Figures

PE Ratio (TTM)

81.79

Margin Of Safety (DCF)

-85.53%

Revenue Growth (5 Year Average)

19.36%

Ratings Consensus

Strong Buy

Share Buybacks

-2.44%

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

3

  • Estimated intrinsic-value of 16.68 USD is lower than current price ( 138.70 USD)
  • Price-to-earnings ratio of 81.8 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 1.15% is worse than the market average (4.7%)
  • Margin-of-safety of -85.53% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 9.1 USD

Current Price: 115.3 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

81.79x

Free Cashflow Yeild

1.15%

PE/Earnings Growth

0.68

Price/Book

21.49x

Growth

Growth Score

59

  • 5 Year Average Revenue growth of 19.36% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • 5 Year Average Cashflow growth of 24.75% is higher than the market average (12.35%)
  • Free Cashflow growth has improved this year
  • 5 Year Average Earnings growth of 0.10% is lower than the market average (14.48%)

Revenue Growth

19.36%

Earnings Growth

0.10%

Cashflow Growth

24.75%

Health

Health Score

56

  • Low risk of bankruptcy
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Has a high level of debt
  • Debt repayments significantly impact cashflow

Altman Z Score

8.12

Piostroski Score

7.00

Debt/Equity

1.34x

Current Assets/Liabilities

1.99x

Free Cashflow/Total Debt

0.11x

Debt/Capital

0.78x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

80

  • Has issued new shares to finance growth when share price is high
  • Return-on-equity of 15.91% is higher than the market average (15%)
  • Return-on-capital-employed of 9.97% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-2.44%

Recent Buybacks/Dilution

-1.00%

5 Year Price Volitility

52.84%

Return On Assets

6.29%

Return On Capital Employed

9.97%

Return On Equity

15.91%

Return On Free Cashflow

N/A

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

94

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

DexCom, Inc.

Currency

USD

Beta

1.154371

Vol Avg

2542047

Ceo

Mr. Kevin Ronald Sayer

Cik

0001093557

Cusip

252131107

Exchange

NASDAQ Global Select

Full Time Employees

7500

Industry

Medical Devices

Sector

Healthcare

Ipo Date

2005-04-14

Address

6340 Sequence Drive

City

San Diego

State

CA

Country

US

Zip

92121

Phone

858 200 0200

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies